ClinicalTrials.gg
Active, not recruitingNCT07183371VAC087Updated Oct 21, 2026

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M

A Phase 2 interventional study of R21 and RH5.1 in Malaria,Falciparum, sponsored by University of Oxford. Active, not recruiting at 1 site in Burkina Faso. Open to participants aged 5 Months to 36 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by University of Oxford · Phase 2, Interventional, and Prevention

How we know

Updated Oct 21, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
5 Months to 36 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Malaria, Falciparum by University of Oxford — 3 open to participants now, 9 under way, 1 of them phase 3. Malaria, Falciparum · University of Oxford.

Planned enrollment
12th of 47
360 · median 62
Started
2025
with 4 others
Phase 2
5 of 54
none open now
Registered
53rd of 54
by date

Among the 54 studies in Malaria, Falciparum by University of Oxford, this one is the 12th largest by planned enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2025, is one of 5 in phase 2, and was the 53rd registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

3 of the 54 studies in Malaria, Falciparum by University of Oxford are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 5 Months to 36 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Malaria, Falciparum by University of Oxford, or all of them as a file.
02

Study summary

This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the malaria vaccine candidates R78C with Matrix-M™, and the combination of RH5.1 and R21 with Matrix-M™, in children aged 5-36 months in Burkina Faso.

Read the detailed description

There will be three study groups, each comprising of 120 children aged between 5 and 36 months at the time of first vaccination living in a malaria endemic area and will be recruited at one site in Burkina Faso. Participants will be randomised to receive either three doses of the malaria candidate vaccines R78C/Matrix-M and three doses of a commercially available rabies vaccine, three doses of RH5.1+R78C/Matrix-M and three doses of R21/Matrix-M or six doses of commercially available control vaccines.

Follow up will be for six months following the last vaccination.

03

Conditions studied

  • Malaria,Falciparum

Browse trials for

04

Who can participate

Ages eligible
5 Months to 36 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Only participants who meet all the inclusion criteria will be enrolled into the trial:

  • Healthy infant aged 5-36 months at the time of first study vaccination
  • Parent/guardian provides signed/thumb-printed
  • Infant and parent/guardian resident in the study area villages and anticipated to be available for vaccination and the duration of follow-up

Exclusion Criteria: The participant may not enter the trial if ANY of the following apply:

  • congenital abnormalities as judged by the PI or other delegated individual.
  • Clinically significant skin disorder (psoriasis, contact dermatitis etc.), cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness as judged by the PI or other delegated individual.
  • Weight-for-age Z score of less than -3 or other clinical signs of malnutrition.
  • History of allergic reaction, significant IgE-mediated event, or anaphylaxis to immunisation.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
  • Sickle cell disease.
  • Clinically significant laboratory abnormality at grade 2 or above as judged by the PI or other delegated individual.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
  • Receipt of any vaccine in the 14 days preceding enrolment, or planned receipt of any other vaccine within 28 days following each study vaccination.
  • History of vaccination with another malaria vaccine.
  • Participation in another research study involving receipt of an product in the 30 days preceding enrolment, or planned use during the study period.
  • Known maternal infection (no testing will be done by the study team).
  • Any confirmed or suspected or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (for , this will mean prednisone, or equivalent, ≥ 0.5 mg/kg/day; inhaled and topical steroids are allowed).
  • Any significant disease, disorder or situation which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.

The following adverse events associated with vaccine immunisation constitute absolute to further administration of vaccine. If any of these events occur during the study, the participant must be withdrawn and followed until resolution of the event, as with any adverse event:

  • Anaphylactic reaction following administration of vaccine.

The following adverse events constitute contraindications to administration of vaccine at that point in time; if any one of these adverse events occurs at the time scheduled for vaccination, the participant may be vaccinated at a later date, or withdrawn at the discretion of the Investigator. The participant must be followed until resolution of the event as with any adverse event:

  • Acute disease at the time of vaccination (acute disease is defined as the presence of a moderate or severe illness with or without fever or symptoms suggestive of possible COVID-19 disease). All vaccines can be administered to persons with a minor illness such as diarrhoea or mild upper respiratory infection without fever, i.e. axillary temperature \< 37.5°C.
  • Temperature of >37.5°C (99.5°F) at the time of vaccination.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Group 1 (n=120) children 5-36 months

    They will receive three doses of 10 µg R78C + 50 µg Matrix-M, administered at Month 0 (Day 0), Month 1 (Day 28), and Month 6 (Day 182). A commercially available rabies vaccine, Rabivax-S, will be administered at Month 3 (Day 98), Month 4 (Day 126) and Month 5 (Day 154). All will be given as a intramuscular injections.

    Biological: R78C · Biological: Matrix-M™ · Biological: Rabivax-S

  • Experimental
    Group 2 (n=120) children 5-36 months

    They will receive three doses of 10 µg RH5.1 + 10 µg R78C + 50 µg Matrix-M, administered at Month 0 (Day 0), Month 1 (Day 28), and Month 6 (Day 182). 5 µg R21 + 50 µg Matrix-M will be administered at Month 3 (Day 98), Month 4 (Day 126) and Month 5 (Day 154), also given as Intramuscular injections. All will be given as intramuscular injections.

    Biological: R21 · Biological: RH5.1 · Biological: R78C · Biological: Matrix-M™

  • Placebo comparator
    Group 3 (n=120) children 5-36 months

    Participants will receive six doses of commercially available control vaccines. This consists of the Hepatitis A vaccine, Avaxim 80, which will be given at Month 0 (Day 0) and Month 6 (Day 182), the meningitis vaccine, Menveo, given at Month 1 (Day 28), and a rabies vaccine, Rabivax-S, given at Month 3 (Day 98), Month 4 (Day 126) and Month 5 (Day 154). All will be given as a intramuscular injections.

    Biological: Rabivax-S · Biological: Menveo · Biological: Avaxim 80

Interventions

  • BiologicalR21

    A protein particle comprising recombinant HBsAg fused to the central repeat and the C-terminus of the circumsporozoite protein

  • BiologicalRH5.1

    A soluble protein vaccine against the RH5 antigen

  • BiologicalR78C

    A soluble RIPR EGF-CyRPA fusion protein vaccine

  • BiologicalMatrix-M™

    A saponin-based vaccine adjuvant

  • BiologicalRabivax-S

    Rabivax-S is an inactivated, freeze-dried, single-dose vaccine. The vaccine contains purified, inactivated rabies antigen produced using Vero ATCC CCL 81 cells as the cell substrate, Pitman Moore (PM3218) as the virus strain, and sucrose, glycine and HSA (Human Serum Albumin) as excipients

  • BiologicalMenveo

    Menveo is a tetravalent meningitis vaccine that consists of one vial of MenA powder and one vial of Men CWY solution.

  • BiologicalAvaxim 80

    Avaxim 80 is an inactivated, adsorbed hepatitis A vaccine. Each immunising dose contains 80 antigen units of inactivated hepatitis A virus (GBM strain).

06

What researchers measure

Primary outcomes

  1. Efficacy: The primary efficacy outcome is clinical malaria, defined as the presence of axillary temperature ≥37.5°C and P. falciparum parasite density >5000 asexual forms/µL.

    To assess the protective efficacy against clinical malaria of R78C with Matrix-M™, and the combination of RH5.1 with Matrix-M™ and R21 with Matrix-M™, in children living in a malaria-endemic area, for 6 months after the final vaccination. Primary case definition for clinical malaria: • Presence of axillary temperature ≥37.5°C and/or history of fever within the last 24 hours AND P. falciparum asexual parasitaemia \> 5000 parasites/µL Secondary case definitions for clinical malaria: * Presence of axillary temperature ≥37.5°C and/ or history of fever within the last 24 hours AND EITHER P. falciparum asexual parasitaemia \>0 parasites/µL OR positive RDT * Presence of axillary temperature ≥37.5°C and/ or history of fever within the last 24 hours AND P. falciparum asexual parasitaemia \>20,000 parasites/µL

    Time frame: Clinical malaria will be assessed 6 months post final vaccination

  2. Safety: To assess the safety and reactogenicity of R78C, RH5.1 and R21 with Matrix-M™ by assessing solicited adverse events (AEs) in children living in a malaria-endemic area until 6 months after administration of the final dose of vaccine.

    The occurrence of solicited local and systemic reactogenicity signs and symptoms will be assessed for 7 days following each vaccination (day of vaccination and 6 subsequent days) Foreseeable adverse reactions following vaccination with RH5.1, R78C or R21 and Matrix-MTM adjuvant are: * Local reactions: pain, erythema, warmth, swelling * Systemic reactions: drowsiness, fever, irritability/fussiness, loss of appetite These AEs will be listed as 'solicited AEs' providing they occur within 7 days of the day of vaccination.

    Time frame: Day 0,1-6,28,29-34,98,99-104,126,127-132,154,155-160,182,183-188.

  3. Safety: To assess the safety and reactogenicity of R78C, RH5.1 and R21 with Matrix-M™ by assessing unsolicited adverse events (AEs) in children living in a malaria-endemic area until 6 months after administration of the final dose of vaccine.

    The occurrence of unsolicited AEs will be assessed for 7 days following each vaccination (day of vaccination and 6 subsequent days). Unsolicited AEs' are AEs other than the foreseeable adverse reactions occurring within the first 7 days, or any AEs occurring after the first 7 days after vaccination. For every unsolicited AE, an assessment of the relationship of the event to the administration of the vaccine will be undertaken by the PI or the PI-delegated clinician. An intervention-related AE refers to an AE for which there is a possible, probable or definite relationship to administration of a vaccine. An interpretation of the causal relationship of the intervention to the AE in question will be made, based on the type of event; the relationship of the event to the time of vaccine administration; and the known biology of the vaccine therapy

    Time frame: Day 0,1-6,14,28,29-34,42,56,98,99-104,112,126,127-132,140,154,155-160,168,182,183-188,196.

  4. Safety: To assess the safety and reactogenicity of R78C, RH5.1 and R21 with Matrix-M™ by assessing serious adverse events (SAEs) in children living in a malaria-endemic area until 6 months after administration of the final dose of vaccine.

    The occurrence of SAEs during the whole study duration. An SAE is an AE that results in any of the following outcomes, whether or not considered related to the study intervention: * Death. * Life-threatening event. This does not include an AE that, if it occurred in a more severe form, might have caused death. * Persistent or significant disability or incapacity. * Hospitalisation or prolongation of hospitalisation, regardless of length of stay, even if it is a precautionary measure for continued observation. Hospitalisation for a pre-existing condition that has not worsened unexpectedly does not constitute an SAE. * An important medical event that may, based upon appropriate medical judgment, jeopardise the volunteer and/or require medical or surgical intervention to prevent one of the outcomes listed above. * Congenital anomaly or birth defect.

    Time frame: Throughout study completion, an average of 1 year

Secondary outcomes

  1. Immunogenicity:To assess the humoral immunogenicity of R78C with Matrix-M™, and the combination of RH5.1 with Matrix-M™ and R21 with Matrix-M™ in children living in a malaria-endemic area.

    Humoral immunogenicity will be assessed from blood samples taken at various timepoints. Immunogenicity will be determined following the quantification of antigen-specific IgG antibody levels (µg/mL readout) over time, as well as by in vitro growth inhibition assays (GIA) against P. falciparum parasites using purified total IgG and a single-cycle pLDH readout assay.

    Time frame: Blood samples for immunogenicity will be taken at Day -30 to 0, 0, 42, 56, 182, 196, 238, and 350.

  2. Efficacy: To assess the protective efficacy against clinical malaria of R78C with Matrix-M™, in children living in a malaria-endemic area, for 3 months after the final vaccination

    The definition for clinical malaria is as follows: 1. Presence of axillary temperature ≥37.5°C and/ or history of fever within the last 24 hours AND EITHER P. falciparum asexual parasitaemia \>0 parasites/µL OR positive RDT or 2. Presence of axillary temperature ≥37.5°C and/ or history of fever within the last 24 hours AND P. falciparum asexual parasitaemia \>20,000 parasites/µL Efficacy will be determined following the comparison of mean parasite density in each study arm

    Time frame: 3 months after the final vaccination

  3. Efficacy: To assess the protective efficacy against clinical malaria of the combination of RH5.1 with Matrix-M™ and R21 with Matrix-M™, in children living in a malaria-endemic area, for 3 months after the final vaccination

    The definition for clinical malaria is as follows: 1. Presence of axillary temperature ≥37.5°C and/ or history of fever within the last 24 hours AND EITHER P. falciparum asexual parasitaemia \>0 parasites/µL OR positive RDT or 2. Presence of axillary temperature ≥37.5°C and/ or history of fever within the last 24 hours AND P. falciparum asexual parasitaemia \>20,000 parasites/µL Efficacy will be determined following the comparison of mean parasite density in each study arm

    Time frame: 3 months after the final vaccination

  4. Efficacy: To assess the protective efficacy against asymptomatic P. falciparum infection of R78C with Matrix-M™, and the combination of RH5.1 with Matrix-M™ and R21 with Matrix-M™, in children living in a malaria-endemic area.

    This will be measured by looking at the following: * Proportion of participants in each study arm that show presence of parasite density \>5000 asexual forms/µL as measured by quantitative reverse-transcriptase PCR (qRT-PCR) from 14 days to 2 and 6 months after administration of the final study vaccination PLUS presence of axillary temperature \<37.5°C and absence of history of fever within the last 24 hours * Proportion of participants in each study arm that show presence of parasite density \>0 asexual forms/µL as measured by qRT-PCR from 14 days to 2 and 6 months after administration of the final study vaccination PLUS presence of axillary temperature \<37.5°C and absence of history of fever within the last 24 hours * Parasite density in those with \>0 asexual forms/µL as measured by qRT-PCR from 14 days to 2 and 6 after administration of the final study vaccination PLUS presence of axillary temperature \<37.5°C and absence of history of fever within the last 24 hours

    Time frame: 2 and 6 months after administration of the final dose of vaccine

  5. Efficacy: To assess the protective efficacy against gametocytaemia of R78C with Matrix-M™, and the combination of RH5.1 with Matrix-M™ and R21 with Matrix-M™, in children living in a malaria-endemic area

    Protective efficacy against gametocytaemia will be assessed by measuring the proportion of participants in each study arm that show the presence of gametocytes \>0 gametocytes/μL as measured by qRT-PCR from 14 days to 2 and 6 months after administration of the final study vaccination

    Time frame: 2 and 6 months after administration of the final dose of vaccine

  6. Efficacy: To assess the protective efficacy of R78C with Matrix-M™, and the combination of RH5.1 with Matrix-M™ and R21 with Matrix-M™, against prevalent moderate or severe anaemia at 6 months after administration of the final dose of vaccine

    Prevalent severe anaemia is defined as a documented haemoglobin (Hb) level \<5.0 g/dL. Prevalent moderate anaemia is defined as a documented Hb level \<8.0 g/dL.

    Time frame: 6 months after administration of the final dose of vaccine

07

Study locations

1 site
  • Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN)
    Nanoro, Burkina Faso
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Mar 2027, 15 months after the start.

Of 39 phase 2 interventional studies under Malaria, Falciparum, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's planned 15 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Dec 2026 → Mar 2027 and completion Dec 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Sep 19, 2025
StartActual
Dec 15, 2025
Primary completionEst.
Mar 2027was Dec 2026
CompletionEst.
Mar 2027was Dec 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Mar 2027
Oct 21, 2026
Study completion
Dec 2026→Mar 2027
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Primary completion Dec 2026→Mar 2027
    Study completion Dec 2026→Mar 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07183371
Collaborators
Institut de Recherche en Sciences de la Sante, Burkina Faso, European and Developing Countries Clinical Trials Partnership (EDCTP), European Vaccine Initiative, Bundesministerium für Forschung, Technologie und Raumfahrt (BMFTR)
Responsible party
Sponsor
First posted
Sep 19, 2025
Start date
Dec 15, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Halidou Tinto
principal investigator · Institut de Recherche en Sciences de la Sante, Burkina Faso

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion